Why the study?
Fetal therapies have been introduced to prevent progression of left heart hypoplasia, improve postnatal outcomes, or secure fetal survival, prompting a review of patient selection and hemodynamic effects in evolving or established HLHS.
Does fetal therapy (invasive cardiac interventions and maternal hyperoxygenation) improve outcomes in fetuses with evolving or established hypoplastic left heart syndrome?
Does fetal therapy (invasive cardiac interventions and maternal hyperoxygenation) improve outcomes in fetuses with evolving or established hypoplastic left heart syndrome?
This review discusses patient selection and hemodynamic effects of fetal cardiac procedures and maternal hyperoxygenation for fetuses with evolving or established hypoplastic left heart syndrome.
Fetal therapies for HLHS with restrictive septum remain investigational; leaves open the need for prospective trials before clinical adoption.
During fetal life some cardiac defects may lead to diminished left heart growth and to the evolution of a form of hypoplastic left heart syndrome (HLHS). In fetuses with an established HLHS, severe restriction or premature closure of the atrial septum leads to left atrial hypertension and remodeling of the pulmonary vasculature, severely worsening an already poor prognosis. Fetal therapy, including invasive fetal cardiac interventions and non-invasive maternal hyperoxygenation, have been introduced to prevent a possible progression of left heart hypoplasia, improve postnatal outcome, or secure fetal survival. The aim of this review is to cover patient selection and possible hemodynamic effects of fetal cardiac procedures and maternal hyperoxygenation in fetuses with an evolving or established hypoplastic left heart syndrome.
No takes yet. Share an insight, caveat, or question.
Tulzer et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: